FUT3抗体;FUT3 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P13433(FUT3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13433(FUT3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

FUT3 antibody targets the FUT3 (Fucosyltransferase 3) enzyme, also known as Lewis enzyme, which is a key glycosyltransferase involved in synthesizing Lewis blood group antigens (e.g., Lewis a, Lewis b). FUT3 catalyzes the transfer of fucose to precursor glycans, forming terminal carbohydrate structures on cell surfaces and secreted glycoproteins. These Lewis antigens play roles in cell-cell recognition, immune response modulation, and microbial adhesion.

FUT3 is highly expressed in epithelial cells and is implicated in various physiological and pathological processes. Aberrant FUT3 activity is linked to cancer progression (e.g., gastrointestinal, pancreatic tumors), where altered Lewis antigen expression affects metastasis and immune evasion. Additionally, FUT3 polymorphisms are associated with inflammatory bowel disease (IBD) susceptibility and Helicobacter pylori infection outcomes due to altered bacterial adhesion.

FUT3 antibodies are critical tools in research and diagnostics. They help detect FUT3 expression in tissues, study glycosylation changes in diseases, and validate its role in cancer biomarkers or therapeutic targets. Commercial FUT3 antibodies are typically developed in rabbit or mouse hosts, validated via Western blot, immunohistochemistry, or flow cytometry. Their specificity ensures accurate profiling of glycosylation patterns, aiding in understanding disease mechanisms and developing targeted therapies.